Antimicrobial Usage Among Acutely Ill Hospitalized Children Aged 2‒23 Months in Sub-Saharan Africa and South Asia
Abstract
Background: Understanding patterns of antimicrobial use is critical to supporting antibiotic stewardship and limiting antimicrobial resistance (AMR). We aimed to describe antimicrobial prescribing in acutely ill hospitalized children aged 2-23 months across a range of rural and urban hospital settings in Sub-Saharan Africa and South Asia.
Methods: The Childhood Acute Illness & Nutrition (CHAIN) cohort collected data daily throughout hospitalization from children with acute illness aged 2-23 months admitted to 9 hospitals from November 2016 to January 2019. We determined proportions of children receiving antimicrobials, inpatient-days receiving antimicrobials, antimicrobial classes, World Health Organization (WHO) Access, Watch, and Reserve (AWaRe) classifications, and examined factors associated with Watch antimicrobial use.
Results: Of 3101 admissions, 1422 (46%) received antimicrobials before hospitalization. A total of 2816 (91%) children received antimicrobials during 19 398/21 807 (93%) inpatient child-days. Two thousand four hundred seventy-seven (76%), 1092 (35%), and 12 (0.3%) children received Access, Watch, and Reserve antimicrobials, mostly within 48 hours of admission. Three hundred forty-one (11%) admissions received an antimicrobial without any indication. Prior admission, chronic illness, diagnoses of sepsis or meningitis, hypoglycemia, and duration of admission were associated with receiving Watch antimicrobials, while WHO danger signs, severe malnutrition,…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.